Eye disease study paves way for gene therapy breakthrough

NCT ID NCT04639635

First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 22 times

Summary

This study looks at a rare genetic eye disease called CNGB1 retinitis pigmentosa, which causes gradual vision loss and blindness. Researchers will follow 20 people over 3 years using eye exams and imaging to track how the disease progresses. The goal is to find the best ways to measure the disease so that future gene therapy trials can test treatments effectively. No treatment is given in this study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA ASSOCIATED WITH CNGB1 MUTATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dr. Stephen H. Tsang

    New York, New York, 10032, United States

  • Eberhard Karls University Tubingen

    Tübingen, Germany

  • Institut de la Vision/Centre de maladies rares du Centre Hospitalier National Ophtalmologique des Quinze-Vingts

    Paris, France

  • Klinikum der Universität München University Eye Hospital, Ludwig-Maximilians-University (LMU) Munich

    München, Bavaria, 80336, Germany

  • Moorfields Eye Hospital NHS Foundation Trust

    London, United Kingdom

  • Wills Eye Hospital

    Philadelphia, Pennsylvania, 19107, United States

Conditions

Explore the condition pages connected to this study.